2-[3-(benzyloxy)phenoxy]ethylamine | 85300-32-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-[3-(benzyloxy)phenoxy]ethylamine
• 英文别名: 2-(3-(benzyloxy)phenoxy)ethanamine；2-(3-phenylmethoxyphenoxy)ethanamine
• CAS: 85300-32-9
• 化学式: C₁₅H₁₇NO₂
• 分子量: 243.305
• InChiKey: LIOIJJQQKDMYBJ-UHFFFAOYSA-N

物化性质

• 沸点：
  398.6±27.0 °C(Predicted)
• 密度：
  1.114±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[3-(benzyloxy)phenoxy]ethylamine 在 吡啶 、 氯化铵 作用下， 以 氯仿 为溶剂， 反应 8.5h， 生成 2-{2-[({2-[2-(benzyloxy)phenoxy]ethyl}amino)carbonyl]phenyl}ethyl ethyl carbonate
  参考文献：
  名称：

  Dopamine/Serotonin Receptor Ligands. 9. Oxygen-Containing Midsized Heterocyclic Ring Systems and Nonrigidized Analogues. A Step toward Dopamine D₅ Receptor Selectivity

  摘要：

  Eleven-membered heterocycles (dibenz[g,j]-1-oxa-4-azacycloundecenes) and open-chain analogues were synthesized and investigated for affinities to human dopamine receptor subtypes. The moderately rigidized rings displayed nanomolar and sulmanomolar K-i values at D-1-like receptors with a significant D-1 to D-2 and a slight D-5 to D-6 selectivity. The open-chain analogues showed lower affinities but significant D-1 to D-2 selectivities. Compound 3 (K-i(D-5) = 0.57 nmol) showed antagonistic or inverse agonistic binding characteristics in a functional Ca assay.

  DOI：

  10.1021/jm049720x
• 作为产物：
  描述：

  3-苄氧基苯酚 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 52.0h， 生成 2-[3-(benzyloxy)phenoxy]ethylamine
  参考文献：
  名称：

  Dopamine/Serotonin Receptor Ligands. 9. Oxygen-Containing Midsized Heterocyclic Ring Systems and Nonrigidized Analogues. A Step toward Dopamine D₅ Receptor Selectivity

  摘要：

  Eleven-membered heterocycles (dibenz[g,j]-1-oxa-4-azacycloundecenes) and open-chain analogues were synthesized and investigated for affinities to human dopamine receptor subtypes. The moderately rigidized rings displayed nanomolar and sulmanomolar K-i values at D-1-like receptors with a significant D-1 to D-2 and a slight D-5 to D-6 selectivity. The open-chain analogues showed lower affinities but significant D-1 to D-2 selectivities. Compound 3 (K-i(D-5) = 0.57 nmol) showed antagonistic or inverse agonistic binding characteristics in a functional Ca assay.

  DOI：

  10.1021/jm049720x

文献信息

• [EN] ALKOXY COMPOUNDS FOR DISEASE TREATMENT<br/>[FR] COMPOSÉS D'ALCOXY POUR LE TRAITEMENT DE MALADIES
  申请人：ACUCELA INC

  公开号：WO2009045479A1

  公开（公告）日：2009-04-09

  The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

  本发明通常涉及治疗神经退行性疾病和紊乱的组合物和方法，特别是治疗眼科疾病和紊乱的组合物和方法。本文提供了烷氧基衍生物化合物和包含这些化合物的药物组合物。所述组合物对治疗和预防眼科疾病和紊乱，包括年龄相关性黄斑变性（AMD）和斯塔加特病（Stargardt's Disease）具有用处。
• Multitarget 1,4-Dioxane Compounds Combining Favorable D₂-like and 5-HT_1A Receptor Interactions with Potential for the Treatment of Parkinson’s Disease or Schizophrenia
  作者：Fabio Del Bello、Dario Ambrosini、Alessandro Bonifazi、Amy H. Newman、Thomas M. Keck、Mario Giannella、Gianfabio Giorgioni、Alessandro Piergentili、Loredana Cappellacci、Antonio Cilia、Silvia Franchini、Wilma Quaglia

  DOI：10.1021/acschemneuro.8b00677

  日期：2019.5.15

  2-methoxy derivative 3 showed a multitarget combination of 5-HT1A/D4 agonism and D2/D3/5-HT2A antagonism, which may be a favorable profile for the treatment of schizophrenia. Interestingly, the 3-hydroxy derivative 8 behaved as a partial agonist at D2 and as a potent full agonist at D3 and D4 subtypes. In addition to its potent 5-HT1A receptor agonism, such a dopaminergic profile makes 8 a potential multitarget

  N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-phenoxyethan-1-amine 骨架苯氧基部分不同位置的甲氧基和羟基取代对亲和力的影响评估了 D2 样、5-HT1A 和 α1-肾上腺素能受体亚型的活性。发现了具有多巴胺能和血清素能谱的合适组合的多目标化合物。特别是，2-甲氧基衍生物 3 表现出 5-HT1A/D4 激动和 D2/D3/5-HT2A 拮抗的多靶点组合，这可能是治疗精神分裂症的有利特征。有趣的是，3-羟基衍生物 8 在 D2 中充当部分激动剂，在 D3 和 D4 亚型中充当有效的完全激动剂。除了其有效的 5-HT1A 受体激动作用外，这种多巴胺能谱使 8 成为治疗帕金森症的潜在多靶点化合物 s 疾病 (PD)。事实上，5-HT1A 受体的激活可能有助于减少与多巴胺能刺激相关的运动障碍副作用。
• Alkoxy compounds for disease treatment
  申请人：Scott Ian L.

  公开号：US20090326074A1

  公开（公告）日：2009-12-31

  The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

  本发明涉及治疗神经退行性疾病和疾病的组合物和方法，特别是眼科疾病和疾病的组合物和方法。本文提供了烷氧基衍生物化合物和包含这些化合物的药物组合物。这些组合物可用于治疗和预防眼科疾病和疾病，包括年龄相关性黄斑变性（AMD）和Stargardt病。
• Alkoxy Compounds for Disease Treatment
  申请人：Scott Ian L.

  公开号：US20120129894A1

  公开（公告）日：2012-05-24

  The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

  本发明通常涉及用于治疗神经退行性疾病和疾病的组合物和方法，特别是眼科疾病和疾病。本文提供了烷氧基衍生物化合物和包含这些化合物的制药组合物。这些化合物对于治疗和预防眼科疾病和疾病，包括年龄相关性黄斑部退化（AMD）和Stargardt病是有用的。
• ALKOXY COMPOUNDS FOR DISEASE TREATMENT
  申请人：Scott Ian L.

  公开号：US20130197096A1

  公开（公告）日：2013-08-01

  The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

  本发明一般涉及用于治疗神经退行性疾病和疾病的组合物和方法，特别是用于治疗眼科疾病和疾病。本文提供了烷氧基衍生物化合物和包含这些化合物的制药组合物。该组合物可用于治疗和预防眼科疾病和疾病，包括年龄相关性黄斑部退化（AMD）和Stargardt病。